MYX mayne pharma group limited

Ann: Mayne Pharma to restate US dermatology net revenue for FY22, page-2

  1. 1,289 Posts.
    lightbulb Created with Sketch. 460
    Sheesh, I don't know whether to laugh or cry.

    Something stank about the dermatology revenues after the AGM, now I'm wondering if they deliberately overstated the revenue for FY22 to avoid breaching debt covenants, so they could restate it later after they had retired all the debt? This is slowly starting to add up...

    Either way, investors bought shares based on the information disclosed for the FY22 results, so watch this space. What I want to see now is some serious on-market purchases by the BOD and skin in the game (once the blackout period has passed.)
    Last edited by Jace1984: 15/02/23
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$5.25
Change
-0.150(2.78%)
Mkt cap ! $426.5M
Open High Low Value Volume
$5.35 $5.41 $5.19 $1.239M 231.7K

Buyers (Bids)

No. Vol. Price($)
1 1000 $5.17
 

Sellers (Offers)

Price($) Vol. No.
$5.36 1000 1
View Market Depth
Last trade - 16.11pm 25/07/2025 (20 minute delay) ?
MYX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.